Cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-21. Numbers and descriptions here follow the published literature rather than marketing material.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Plutonium-241 (241Pu, Pu-241) is an isotope of plutonium formed when plutonium-240 captures a neutron. Like some other plutonium isotopes (especially 239Pu), 241Pu is fissile, with a neutron absorption cross section about one-third greater than that of 239Pu, and a similar probability of fissioning on neutron absorption, around 73%. In the non-fission case, neutron capture produces plutonium-242. In general, isotopes with an odd number of neutrons are both more likely to absorb a neutron and more likely to undergo fission on neutron absorption than isotopes with an even number of neutrons.
==== Rodent research ==== A study on the fossil record of Asian rodents spanning the last 55 million years, providing evidence of impact of tectonic and climatic changes on ecomorphological diversity of Asian rodent assemblages throughouth their evolutionary history, is published by Peng & Hopkins (2026). Pfaff, Ruf & Le Maître (2026) determine the locomotory behavior of extinct members of Eusciurida on the basis of the study of middle and inner ear of extant and extinct rodents, interpreting early rodents and sciurids as fossorial, with adaptations to arboreal lifestyle evolving in later taxa. Review of research on systematics of fossil dormice from Mediterranean islands from the preceding years is published by Fox & Hennekam (2026). Wei et al. (2026) reconstruct the evolutionary history of marmots on the basis of paleontological and molecular data. Murchie et al. (2026) report evidence of preservation of ancient environmental DNA of diverse Quaternary organisms from eastern Beringia in the Pleistocene and Holocene ground squirrel coprolites from Yukon (Canada), including evidence of previously unrecognized genetic diversity of Arctic members of the genus Urocitellus. Li, Bi & Li (2026) present the first virtual endocasts of Paleogene ctenodactyloids Exmus mini and Bounomys ulantatalensis. The first fossil material of Hystrix subcristata from Taiwan is reported from the Pleistocene Chiting Formation by Halaçlar & Lin (2026). Buldrini et al. (2026) describe fossil material of Phugatherium sp.
According to Jay Garfield, in the first chapter, Nāgārjuna argues against a reified view of causality which sees dependent origination in terms of substantial powers (kriyā) of causation (hetu) that phenomena have as part of their intrinsic nature (svabhāva). Instead, Nāgārjuna sees dependent origination as a series of conditional relationships (pratyaya) that are merely nominal designations and "explanatorily useful regularities". According to Nāgārjuna, if something could exist inherently or essentially from its own side (and thus have its own inherent causal powers), change and dependent arising would be impossible. Nāgārjuna states that "if things did not exist without essence, the phrase, "when this exists so this will be," would not be acceptable." Jan Westerhoff notes that Nāgārjuna argues that cause and effect are "neither identical nor different nor related as part and whole, they are neither successive, nor simultaneous, nor overlapping." Westerhoff states that Nāgārjuna thinks all conceptual frameworks of causality that make use of such ideas are based on a mistaken presupposition which is that "cause and effect exist with their own svabhāva". Westerhoff further argues that for Nāgārjuna, causes and effects are both dependent on one another (conceptually and existentially) and neither one can exist independently. As such, he rejects four ways that something could be causally produced: by itself, by something else, by both, by nothing at all.
The states of the Federal Republic of Germany, and so Lower Saxony, have legislative responsibility and power mainly reduced to the policy fields of the school system, higher education, culture and media and police, while other policy fields like economic and social policies, foreign policy are a prerogative of the federal government. Hence the probably most important function of the federal states is their representation in the Federal Council (Bundesrat), where their approval on many crucial federal policy fields, including the tax system, is required for laws to become enacted.
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) are a class of medication used primarily for the treatment of cardiovascular and kidney diseases. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart. ACE inhibitors inhibit the activity of angiotensin-converting enzyme, an important component of the renin–angiotensin system which converts angiotensin I to angiotensin II, and hydrolyzes bradykinin. Therefore, ACE inhibitors decrease the formation of angiotensin II, a vasoconstrictor, and increase the level of bradykinin, a peptide vasodilator. This combination is synergistic in lowering blood pressure. As a result of inhibiting the ACE enzyme in the bradykinin system, the ACE inhibitor drugs allow for increased levels of bradykinin which would normally be degraded. Bradykinin produces prostaglandin. This mechanism can explain the two most common side effects seen with ACE Inhibitors: angioedema and cough.
Sources: en.wikipedia.org
Stability of isotopes is affected by the ratio of protons to neutrons, and also by presence of certain magic numbers of neutrons or protons which represent closed and filled quantum shells. These quantum shells correspond to a set of energy levels within the shell model of the nucleus; filled shells, such as the filled shell of 50 protons for tin, confers unusual stability on the nuclide. As in the case of tin, a magic number for Z, the atomic number, tends to increase the number of stable isotopes for the element. Just as electrons have the lowest energy state when they occur in pairs in a given orbital, nucleons (both protons and neutrons) exhibit a lower energy state when their number is even, rather than odd. This stability tends to prevent beta decay (in two steps) of many even–even nuclides into another even–even nuclide of the same mass number but lower energy (and of course with two more protons and two fewer neutrons), because decay proceeding one step at a time would have to pass through an odd–odd nuclide of higher energy. Such nuclei thus instead undergo double beta decay (or are theorized to do so) with half-lives several orders of magnitude larger than the age of the universe. This makes for a larger number of stable even–even nuclides, which account for 150 of the 251 total. Stable even–even nuclides number as many as three isobars for some mass numbers, and up to seven isotopes for some atomic numbers.
=== Initial analogue development (1996–2014) === The development of insulin analogues began with Humalog (insulin lispro), a short-acting insulin analogue developed by Eli Lilly, which was approved by the FDA in 1996. Humalog was designed to be absorbed more quickly than regular insulin, offering improved flexibility in meal timing and postprandial glucose control. In 2000, Lantus (insulin glargine) was approved by the FDA and the European Medicines Agency (EMA). Lantus is a long-acting insulin analogue designed to provide a steady basal level of insulin throughout the day, typically lasting up to 24 hours, thereby reducing the need for multiple daily injections. In 2004, Apidra (insulin glulisine), another short-acting insulin analog, was approved by Sanofi-Aventis to improve postprandial glucose control. In 2005, Levemir (insulin detemir), developed by Novo Nordisk, was approved for clinical use. Levemir is a long-acting insulin analogue similar to Lantus but with a slightly shorter duration of action. It provides stable basal insulin coverage with a reduced risk of hypoglycemia compared to older insulins.
They further argued, "In contrast, Moscow's timing suggests that Putin seeks to overthrow Saakashvili well ahead of our elections, and thus avoid beginning relations with the next president on an overtly confrontational note." They stated that Russia could attack Ukraine next. Former employee of the United States Department of Defense said that Russia wanted to change the government of Georgia and install a satrap. Member of the Parliament of the United Kingdom Bruce George said that he had no doubt that the South Ossetians were incited by Russia to launch the attack. Matthew Bryza, Deputy Assistant Secretary of State, said on 11 August that Russia had planned to invade Georgia beforehand and cited the deployment of the Russian railway troops to Abkhazia as proof. Senator John McCain said that NATO's refusal to offer membership to Georgia in April 2008 "might have been viewed as a green light by Russia for its attacks on Georgia." Ronald Asmus wrote on 12 August 2008 that the West was responsible for the propagation of Russia's role as peacekeeper. Asmus recalled that his European friend was advised by Russian official in late July 2008 to visit Georgia sooner because it could be late in September 2008. The New York Times reported on 12 August 2008 that Bush administration had been warning Georgia not to become involved in the conflict with Russia.
The results of studies which have looked at healing of electrosurgical wounds compared to scalpel wounds vary widely but it has been found that electrosurgerical equipment minimises bleeding and most patients experience very little post-operative pain after the procedure. There may be more damage to adjacent tissues, slower wound healing and more inflammatory response than the scalpel technique.
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.